ArticleBMC musculoskeletal disorders2026
Bone versus soft tissue hydatid disease: a retrospective comparative cohort study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMusculoskeletal hydatid disease is uncommon and often mimics neoplastic lesions. Comparative evidence between bone and soft tissue involvement remains limited. We aimed to compare demographic characteristics, laboratory parameters and surgical outcomes between bone and soft tissue hydatid disease in an endemic region.
methodsWe retrospectively reviewed 64 consecutive patients who underwent surgery for histopathologically confirmed musculoskeletal hydatid disease between January 2010 and January 2024 (bone, n = 26; soft tissue, n = 38). Groups were compared regarding demographics, presenting symptoms, inflammatory indices White Blood Cell Count (WBC), Erythrocyte Sedimentation Rate (ESR), and C-Reactive Protein (CRP), Eosinophil count, Eosinophil-to-Lymphocyte Ratio (ELR), hemagglutination test, cyst morphology (uni- vs. multilocular), complications, concomitant liver/lung involvement, and recurrence. Appropriate parametric/non-parametric and categorical tests were used.
resultsDemographic characteristics and baseline WBC/ESR/CRP and hemagglutination positivity did not differ between groups. Bone involvement presented predominantly with pain (22/26, 84.6%), whereas soft tissue disease frequently presented with isolated swelling (20/38, 52.6%) (p = 0.001). Eosinophil count (2.00 ± 1.26 vs. 0.89 ± 0.68; p = 0.013) and ELR (0.23 ± 0.13 vs. 0.12 ± 0.08; p = 0.014) were significantly higher in bone disease. Bone involvement had higher rates of intraoperative rupture (20/26, 76.9% vs. 10/38, 26.3%; p = 0.005), concomitant organ involvement (14/26, 53.8% vs. 8/38, 21.1%; p = 0.045), and recurrence (20/26, 76.9% vs. 8/38, 21.1%; p = 0.002). Multiloculated morphology was more frequent in soft tissue lesions (30/38, 78.9% vs. 10/26, 38.5%; p = 0.005). Among the cases treated for bone hydatid cysts, recurrence was observed in 20 out of 26 patients, while anaphylaxis occurred in 15 out of 26 patients during surgery. In contrast, among 38 patients who underwent surgery for soft tissue hydatid cysts, recurrence was observed in 8 (p = 0.002) and anaphylaxis developed in 7 during surgery (p = 0.041).
conclusionsBone hydatid disease demonstrates a more aggressive clinical course than soft tissue disease, with substantially higher rupture, recurrence, and concomitant organ involvement rates. Elevated eosinophil count and ELR at presentation may support the suspicion of bone involvement. Future prospective studies incorporating multivariable modeling are warranted to identify independent predictors of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.